パーキンソン病治療薬のアメリカ市場:市場インサイト、疫学分析、市場予測

DelveInsightが発行した調査報告書(DLVE704013)
◆英語タイトル:Parkinson Disease - Market Insights, Epidemiology and Market Forecast – 2023 - United States
◆商品コード:DLVE704013
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2017年1月
◆ページ数:88
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2営業日以内)
◆調査対象地域:米国
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD2,450 ⇒換算¥276,850見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD4,900 ⇒換算¥553,700見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD7,350 ⇒換算¥830,550見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

DelveInsight’s “Parkinson Disease – Market Insights, Epidemiology and Market Forecast – 2023 – United States” Reports provides an overview of the disease and global market size of the Parkinson Disease for the United States. It also includes global historical and forecasted epidemiological data for the diagnosed prevalent cases of Parkinson Disease from 2010-2023. According to Publisher, the forecasted patient population of Parkinson Disease will increase at a CAGR of XX% from 2010 to 2023 and the worldwide Parkinson Disease market is estimated to be USD XX Million by 2023.Parkinson’s disease (PD) is a disorder caused by the malfunction and death of neurons. It is a chronic and progressive movement disorder which primarily affects neurons in substantia nigra area of the brain. Dopamine is usually responsible for the control and coordination process which is affected when the neuron malfunction and death occurs. As the disease progresses, the amount of dopamine produced in the brain decreases as a result the person is unable to control movement normally. This degenerative disorder affects the central nervous system.
Scope
- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
- Marketed information including available prescription drugs, its patent and exclusivity details.
- The Report also covers the detailed global historical and forecasted epidemiological data covering United States from 2010-2023.
- It also provides Market size of Parkinson disease for United States from 2010 and forecasted Market size to 2023.

【レポートの目次】

Report Introduction
Parkinson Disease Market Overview at a Glance
Total Market Size of Parkinson Disease for 7 MM in 2013-2023
Total Market Share Distribution of Parkinson Disease for 7 MM in 2015
Total Market Share Distribution of Parkinson Disease for 7 MM in 2023
Parkinson Disease
Overview
Symptoms
Pathophysiology
Staging
Diagnosis
Treatment
Epidemiology and Patient Population
United States
Diagnosed Cases of Parkinson Disease in United States
Marketed Drugs
Top Marketed Drugs for Parkinson disease
Azilect: Teva Pharmaceutical Industries
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Azilect
Product Profile
Exelon/Exelon Patch: Novartis
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Exelon
Product Profile
Stalevo: Orion Corporation
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Stalevo
Product Profile
Comtan/Comtess: Orion Corporation
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Comtan/Comtess
Product Profile
Emerging Therapies
Major Pipeline drugs
Istradefylline
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Tozadenant
Advantages & Disadvantages
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
CVT-301
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Global Parkinson Disease: Country-Wise Market Analysis
Overview on Total Parkinson Disease Market (2015 & 2023)
United States Market Size
Market Drivers
Market Restraints
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight

Table 1: Diagnosed Cases Parkinson Disease in United States (2010-2023)
Table 2: List of Marketed Drugs for Parkinson Disease
Table 3: List of Pipeline Phase III Drugs for Parkinson Disease
Table 4: Istradefylline, Clinical Trials by Zone, 2016
Table 5: Clinical Trials by Trial status, 2016
Table 6: Tozadenant, Clinical Trials by Zone, 2016
Table 7: Clinical Trials by Trial status, 2016
Table 8: CVT-301, Clinical Trials by Zone, 2016
Table 9: Clinical Trials by Trial status, 2016
Table 10: United States Market Size of Parkinson Disease in USD, Million (2010-2023)


Figure 1: Types of Parkinson Disease
Figure 2: Types of Parkinson Disease
Figure 3: Diagnosed Cases of Parkinson Disease in United States (2010-2023)
Figure 4: Istradefylline, Clinical Trials by Zone (%), 2016
Figure 5: Istradefylline, Clinical Trials by Trial status (%), 2016
Figure 6: Tozadenant, Clinical Trials by Zone (%), 2016
Figure 7: Istradefylline, Clinical Trials by Trial status (%), 2016
Figure 8: CVT-301, Clinical Trials by Zone (%), 2016
Figure 9: CVT-301, Clinical Trials by Trial status (%), 2016
Figure 10: Total Market Size of Parkinson Disease in USD, Million (2015)
Figure 11: Total Market Size of Parkinson Disease in USD, Million (2023)
Figure 12: United States Market Size of Parkinson Disease in USD, Million (2010-2023)


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ パーキンソン病治療薬のアメリカ市場:市場インサイト、疫学分析、市場予測(Parkinson Disease - Market Insights, Epidemiology and Market Forecast – 2023 - United States)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆